We want to welcome @Geovax_News to the @ROTHCapital Partners 3rd Annual Healthcare Opportunities Conference October 9th. See their profile on @B2iDigital at https://t.co/5MsVsQ9rvX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24)
We look forward to seeing the continued results from David A. Dodd, Arban Domi, Mary Hauser, Susan Hensley, MS, RAC, Kelly McKee, Mark Newman, John Niles, Tom O'Brien, Sreenivasa Rao Oruganti, J. Marc Pipas, MD, Erica Raiden, Mark Reynolds, John W. Sharkey, Jeff Welch, Ashley Zuniga, PhD PMP and the entire GeoVax Labs, Inc. team!
Thanks to the stellar team at ROTH for organizing this conference: Sagar Sheth, Byron Roth, Isabel Mattson-Pain, Amanda McAdams, Otilia "Charo" Montano, Benjamin Bowen, James Antonopoulos, Jason Wittes, Jonathan Aschoff, Ph.D., Boobalan Pachaiyappan, Ph.D. and many others
ROTH is a relationship-driven investment bank headquartered in Newport Beach, CA. For more information on ROTH, please visit https://t.co/f7LaejqxRB.
We hope you’ll be able to attend this pivotal event shaping the future of healthcare innovation.
So this is really important - contingency plans for discontinued drugs, devices and diagnostics...there is no one size fits all in healthcare! #insulin
Registration Is Now Open for Tribe Public’s Webinar Event
"Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO. https://t.co/V9KC6IDCP9 #mpox#vaccine $GOVX
Have a question about the state of an #Mpoxvaccine ? $GOVX GeoVax Labs to Present at the Emerging Growth Conference on August 21, 2024
[email protected]
#ICYMI: MSM has received a generous commitment of $175 million from @MikeBloomberg and @BloombergDotOrg to support our endowment! 🌟
This gift will further our mission of leading the creation and advancement of health equity. 🩺
Learn more: https://t.co/cIJPcAx2S2
Venture Capital Podcast revealed its Founder 100 list for Utah! BioUtah members that made the list include:
• David Bearss – Halia Therapeutics
• Chiao-ih Hui, Solution Diagnostics
• Mark Newman – Nomi Health
• Kurt Workman – Owlet
https://t.co/95wcOg13WU
$350 Million, 10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA’s Clinical Studies Network. https://t.co/zxe3NnlXRl